Media stories about Conatus Pharmaceuticals (NASDAQ:CNAT) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.5468191376484 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
CNAT has been the subject of several recent analyst reports. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Seaport Global Securities reiterated a “buy” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.00.
Shares of Conatus Pharmaceuticals (CNAT) opened at $4.10 on Friday. Conatus Pharmaceuticals has a 52 week low of $1.81 and a 52 week high of $9.40. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.41.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The firm had revenue of $9.57 million for the quarter, compared to analysts’ expectations of $16.06 million. During the same quarter last year, the firm posted ($0.31) earnings per share. research analysts predict that Conatus Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.
WARNING: This article was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.truebluetribune.com/2017/12/10/conatus-pharmaceuticals-cnat-earns-coverage-optimism-score-of-0-14.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.